---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-26-000005"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:45:53.804581+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma 2025 rev ~$854-873M, Cortrophin Gel up 76% YoY; 2026 rev target $1.06-1.12B

## Summary
- Full-year 2025 total net revenues expected within or above $854M-$873M guidance ( ~39% YoY growth).
- Cortrophin Gel net rev $347.8M in 2025 (+76% YoY); Q4 Cortrophin Gel $111.4M (+88% YoY).
- 2026 guidance: total net rev $1,055M-$1,115M, Cortrophin Gel $540M-$575M, adj EBITDA $275M-$290M, adj EPS $8.83-$9.34.
- Plans to expand Rare Disease sales force by ~90 in mid-2026 to target acute gouty arthritis flares.
- Unrestricted cash $285M at Dec 31, 2025; ILUVIEN+YUTIQ combined rev $74.9M in 2025.

## SEC filing metadata
- accession: 0001023024-26-000005
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/0001023024-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/ani-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-26-000005
- JSON: https://secwatch.observer/filing/0001023024-26-000005.json
- Plain text: https://secwatch.observer/filing/0001023024-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.